Skip to main content

Table 1 Clinical characteristics and autoantibody profiles of patients at time of muscle biopsy a and results of immunohistochemical analysis of biopsies

From: Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies

Patient

Dg

Years since Dg

Anti-Jo-1

Anti-Ro52

Anti-Ro60

Other autoantibodies

Treatment duration (yr)

Treatment at time of biopsy

Cumulative clinical manifestations

Infiltrate score**

BAFF-R

BCMA

TACIb

CD19

CD138

TACI/vesselb

1

Def PM

−0.8

+

0

No

ILD, A, R

3

+

+

+

+

+

2

Def PM

0

+

RNP-70

0

No

ILD

0

-

+

+

3

Def PM

0.4

+

Ku-72

0.3

Yes

ILD, A, R, MH, SS

0

NA

NA

NA

4

Def PM

1.6

+

1.6

Yes

ILD, E, T

2

+

+

5

Prob PM

2.9

+

2.8

Yes

ILD

3

+

+

+

+

+

6

Prob DM

22.5

+

+

+

La, Ku-86

28.5

Yes

ILD, R, SR

2

+

7

Prob PM

6.5

+

+

La

6.4

Yes

A, pSS

3

+

+

+

+

+

+

8

Def IBM

0.5

+

+

La

0.4

Yes

pSS

3

+

+

+

+

+

9

Def PM

0.2

+

0.2

Yes

ILD, R

2

NA

NA

+

10

Def IBM*

0

+

13.7

Yes

R

2

+

NA

NA

+

11

Def DM

8.8

Mi-2, PM-Scl

9.0

Yes

SR, SS

2

+

+

12

Def PM

0.8

0.5

Yes

 

0

13

Prob PM

−0.1

0

No

 

2

+

+

14

Prob DM

0

0

No

SR

0

+

15

Def PM

5.0

4.9

Yes

 

2

+

+

16

Def IBM

0.8

Histones

0.8

Yes

E

2

+

+

+

17

Def IBM*

0

9.0

Yes

R

1

+

+

+

18

Def DM

0.3

0.3

Yes

SR

1

NA

NA

+

19

Prob DM

0.1

0.2

Yes

SR

2

+

NA

NA

+

20

Def IBM

8.4

8.4

Yes

 

0

NA

NA

+

21

Def PM

9.4

9.7

Yes

A

0

NA

NA

+

22

Def DM

13.2

Ku-86

13.2

Yes

SR

1

23

Prob IBM*

−1.1

2.1

Yes

 

0

+

NA

NA

+

  1. aA, Arthritis; BAFF-R, B-cell-activating factor of the tumour necrosis factor family receptor; BCMA, B-cell maturation antigen; Def, Definitive; Dg, Diagnosis; DM, Dermatomyositis; E, oesophagus; IBM, Inclusion body myositis; ILD, Interstitial lung disease; MH, Mechanic’s hands; NA, Not assessed; PM, Polymyositis; Prob, Probable; pSS, Primary Sjögren’s syndrome; R, Raynaud’s phenomenon; SR, Skin rash; SS, Sjögren’s syndrome; T, Thrombosis; TACI, Transmembrane activator and calcium modulator and cyclophilin ligand interactor. bTACI was also expressed in vessels (*) at time of biopsy diagnosed as PM, (**) score: 0=no infiltrate; 1=scattered cells; 2=one or two small infiltrates; 3=several small or one big infiltrate or infiltrate + scattered cells.